A Phase 2 interventional study of CT-868 and CT-868 Pen Injector in Overweight, Obese and Type 1 Diabetes Mellitus, sponsored by Carmot Therapeutics, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Overweight by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Overweight · Hoffmann-La Roche.
Among the 20 studies in Overweight by Hoffmann-La Roche, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 7 in phase 2, and was the 5th registered.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
Browse Overweight studies →8 of the 20 studies in Overweight by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, Taiwan, United Kingdom
Ages 40+
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 78 across 3,142 interventional studies indexed under Overweight.
Median enrollment 326 across the 20 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Carmot Therapeutics, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Carmot Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
3 of the studies in Overweight by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT07499050Hoffmann-La RocheA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight | 2027-01-09 |
| NCT07589686Hoffmann-La RocheA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Overweight by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 1.8 mg, and it will be administered once daily for a total duration of 16 weeks.
Drug: CT-868 · Device: CT-868 Pen Injector
Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 4.1 mg, and it will be administered once daily for a total duration of 16 weeks.
Drug: CT-868 · Device: CT-868 Pen Injector
Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 6.6 mg, and it will be administered once daily for a total duration of 16 weeks.
Drug: CT-868 · Device: CT-868 Pen Injector
Participants in this arm will receive a placebo designed to match the appearance and formulation of the drug CT-868. The intervention consists of a subcutaneous injection of this placebo. The placebo will be administered once daily for a duration of 16 weeks.
Device: CT-868 Pen Injector · Drug: CT-868 Pen Injector, Placebo
CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
Also known as: Acmopatide, RO7795074
The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
The placebo pen injector is identical and contains the same ingredients except for CT-868.
Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16
Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the mixed-effect model of repeated measures (MMRM).
Time frame: Baseline (Day 1) to Week 16
Percent Change From Baseline in Body Weight at Week 16
Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.
Time frame: Baseline (Day 1) to Week 16
Change From Baseline in HbA1c (%) at Weeks 4, 8, and 12
Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.
Time frame: Baseline (Day 1) to Weeks 4, 8, and 12
Percentage of Participants Achieving HbA1c Target of <7.0% at Week 16
Percentages have been rounded off.
Time frame: At Week 16
Percentage of Participants Achieving HbA1c Target of ≤6.5% at Week 16
Percentages have been rounded off.
Time frame: At Week 16
Percentage of Participants Achieving HbA1c Target of <5.7% at Week 16
Time frame: At Week 16
Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16
Baseline was defined as the median daily insulin dose (units per day \[units/day\]) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16. Total daily insulin dose was only calculated when daily bolus and daily basal are both present.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in Basal Insulin Dose at Weeks 8 and 16
Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16
Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.
Time frame: Baseline (Day 1), Weeks 8 and 16
Percent Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16
Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Percent Change From Baseline in Basal Insulin Dose at Weeks 8 and 16
Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Percent Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16
Baseline bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Percent Change From Baseline in Body Weight-adjusted Total Daily Insulin Dose at Weeks 8 and 16
Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM. units/kg/day=units per kilograms per day.
Time frame: Baseline (Day 1), Weeks 8 and 16
Percent Change From Baseline in Body Weight-adjusted Basal Insulin Dose at Weeks 8 and 16
Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Percent Change From Baseline in Body Weight-adjusted Bolus Insulin Dose at Weeks 8 and 16
Baseline of bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in Continuous Glucose Monitoring (CGM) Intraday Mean Sensor Glucose
All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\< 8.5% or ≥ 8.5%) + Methods of insulin administration (pump or multiple daily injection \[MDI\]) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in CGM Interday Mean Sensor Glucose
All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in Percentage of Time Spent in Range (TIR) 70-180 mg/dL
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in Percentage of TIR 70-140 mg/dL
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-140 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in CGM Percent Time Spent in Level 1 Hypoglycemia (Time Below Target Range [TBTR, <54-70 mg/dL]) and Level 2 Hypoglycemia (Time Very Below Target Range [TVBTR <54 mg/dL])
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay below the target range of \<54-70 mg/dL and very below the target range of \<54 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Change From Baseline in CGM Percent Time Spent in Level 1 Hyperglycemia (Time Above Target Range [TATR, >180-250 mg/dL]) and Level 2 Hyperglycemia (Time Very Above Target Range [TVATR >250 mg/dL])
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay TATR \>180-250 mg/dL and TVATR \>250 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
Time frame: Baseline (Day 1), Weeks 8 and 16
Event Rate With Sensor Glucose <70 mg/dL Lasting at Least 120 Minutes
All participants used a CGM device for glucose monitoring throughout the treatment. Data is reported for event rate (number of events per person-year). Number of events with sensor glucose \<70 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≥70 mg/dL for ≥15 minutes) was assessed. Percentages have been rounded off.
Time frame: Weeks 8 and 16
Event Rate With Sensor Glucose >250 mg/dL Lasting at Least 120 Minutes
All participants used a CGM device for glucose monitoring throughout the treatment. Data are reported for event rates. Event=sensor glucose \>250 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≤180 mg/dL for ≥15 minutes). Percentages have been rounded off.
Time frame: Weeks 8 and 16
Number of Participants With TIR 70-180 mg/dL With ≥5% Points Improvement From Baseline
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.
Time frame: At Weeks 8 and 16
Number of Participants With TIR 70-180 mg/dL With ≥10% Points Improvement From Baseline
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.
Time frame: At Weeks 8 and 16
Number of Participants With TIR 70-180 mg/dL for >70% of the 14-day Collection Interval Around the Week 8 Visit and the 14-day Interval Prior to the Week 16 Visit
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.
Time frame: At Weeks 8 and 16
Number of Participants With Time Below Range (TBR) <70 mg/dL for <4% of Each Day
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With TBR <54 mg/dL for <1% of Each Day
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With Time Above Range (TAR) >180 mg/dL for <25% of Each Day
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With TAR >250 mg/dL for <5% of Each Day
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With TBR <70 mg/dL for <4% Over the 14-day Collection Window
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With TBR <54 mg/dL for <1% Over the 14-day Collection Window
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With TAR >180 mg/dL for <25% Over the 14-day Collection Window
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Number of Participants With TAR >250 mg/dL for <5% Over the 14-day Collection Window
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Percent Change From Baseline in the Glycemic Risk Index
All participants used a CGM device for glucose monitoring throughout the treatment.
Time frame: Baseline, Weeks 8 and 16
Percent Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16
Time frame: Baseline (Day 1), and Weeks 4, 8, 12, and 16
Absolute Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16
Time frame: Baseline (Day 1), and Weeks 4, 8, 12, and 16
Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16
Time frame: At Week 16
Percentage of Participants Experiencing 1 or More Level 1, 2, or 3 Hypoglycemia Events (Worst Severity)
Level 1 hypoglycemia: glucose between \<70-54 mg/dL; Level 2 hypoglycemia: glucose level between \<54 mg/dL; Level 3 hypoglycemia: These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma.
Time frame: Postbaseline from Day 1 to Week 16
Event Rate of Level 2 Hypoglycemia Over the 2-Week Baseline Period and the 16-Week Treatment Period
The baseline period event rate was calculated as (the total number of events) / (14/365.25 \* number of patients). Baseline hypoglycemia events occurred within 14 days prior to first treatment start time (Day 1). The treatment period event rate was calculated as (the total number of events) / (sum of the person-time exposed to the study drug after randomization (in years)). Sum of the person-time exposed to the study drug after randomization is calculated as the time from first to last dose of study drug for all participants in the respective treatment arm.
Time frame: Baseline Period (14 days before Day 1) and Treatment Period (up to 16 weeks)
Number of Participants With Diabetic Ketoacidosis (DKA) Events
DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 milliequivalents per liter \[mEq/L\]), and accompanied by symptoms/signs per the anti-drug antibody (ADA) consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.
Time frame: Up to Week 18
Participants With DKA Events That Led to Hospitalization or Emergency Room Visits During the Study
DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 mEq/L), and accompanied by symptoms/signs per the ADA consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.
Time frame: Up to Week 18
Number of Participants With Adverse Events (AEs) and Adverse Device Effects (ADEs) Over the Period of 16 Weeks
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An ADE was defined as an AE related to the medical device; in this study, the medical device is the pen device with which the study drug is administered. This included any event that was the result of incomplete user manual information or of incorrect use of the medical device.
Time frame: Up to 16 weeks
Plasma Drug Concentrations of CT-868 at the Weeks 2, 4, 6, 8, 12, and 16 Visits
Time frame: At 24 hours post-dose on Weeks 2, 4, 6, 8, 12, and 16
A total of 111 overweight and obese adult participants with type 1 diabetes mellitus (T1DM) took part in the study from 27 November 2023 to 07 July 2025 across 22 sites in the United States.
| Milestone | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Started | 29 | 27 | 28 | 27 |
| Safety population | 29 | 30 | 34 | 18 |
| Completed | 22 | 23 | 24 | 25 |
| Not completed | 7 | 4 | 4 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 | 0 |
| Withdrew: Reason not specified | 2 | 1 | 2 | 2 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the mixed-effect model of repeated measures (MMRM).
| percentage | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16 | -0.25 ± 0.101 | -0.43 ± 0.105 | -0.59 ± 0.101 | -0.45 ± 0.104 |
Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.
| percentage change | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 16 | 0.29 ± 0.839 | -3.26 ± 0.865 | -6.43 ± 0.838 | -6.67 ± 0.861 |
Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.
| percentage | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.08 ± 0.067 | -0.17 ± 0.069 | -0.30 ± 0.068 | -0.20 ± 0.070 |
| Change at Week 8 | -0.17 ± 0.087 | -0.35 ± 0.091 | -0.46 ± 0.086 | -0.24 ± 0.090 |
| Change at Week 12 | -0.27 ± 0.099 | -0.36 ± 0.103 | -0.52 ± 0.098 | -0.35 ± 0.102 |
Percentages have been rounded off.
| percentage of participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving HbA1c Target of <7.0% at Week 16 | 36.4 | 45.0 | 66.7 | 40.9 |
Percentages have been rounded off.
| percentage of participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving HbA1c Target of ≤6.5% at Week 16 | 9.1 | 20.0 | 33.3 | 27.3 |
| percentage of participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving HbA1c Target of <5.7% at Week 16 | 0 | 0 | 0 | 0 |
Baseline was defined as the median daily insulin dose (units per day \[units/day\]) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16. Total daily insulin dose was only calculated when daily bolus and daily basal are both present.
| units/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 82.40 (27.9 to 113.1) | 68.80 (24.1 to 225.0) | 56.00 (4.0 to 166.2) | 59.00 (29.5 to 109.5) |
| Change at Week 8 | -3.00 (-73.0 to 16.8) | -6.35 (-30.0 to 25.3) | -18.00 (-74.0 to 7.0) | -12.39 (-47.8 to 17.8) |
| Change at Week 16 | -4.50 (-73.0 to 50.5) | -5.80 (-75.0 to 34.5) | -9.33 (-36.4 to 25.4) | -15.00 (-49.9 to 20.1) |
Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.
| units/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 34.4 (18.5 to 80.0) | 35.0 (16.1 to 110.0) | 37.0 (0.0 to 160.0) | 33.8 (16.0 to 69.5) |
| Change at Week 8 | 0.0 (-14.1 to 11.4) | -0.9 (-10.2 to 5.8) | -2.8 (-24.0 to 5.7) | -3.7 (-16.9 to 6.7) |
| Change at Week 16 | 0.0 (-13.0 to 10.0) | 0.0 (-14.5 to 6.0) | -0.5 (-13.0 to 12.0) | -2.0 (-21.7 to 7.7) |
Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.
| units/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 32.80 (9.2 to 81.0) | 30.79 (6.0 to 115.0) | 26.45 (4.0 to 102.5) | 25.00 (5.0 to 66.0) |
| Change at Week 8 | -1.75 (-62.0 to 31.9) | -2.91 (-25.5 to 19.5) | -10.15 (-60.9 to 7.0) | -8.09 (-33.0 to 12.2) |
| Change at Week 16 | -5.00 (-63.8 to 52.0) | -7.08 (-70.0 to 34.5) | -7.80 (-30.0 to 27.0) | -6.20 (-36.0 to 9.8) |
Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
| Percentage change in units/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change at Week 8 | -8.32 ± 7.653 | -2.33 ± 8.792 | -24.25 ± 9.119 | -21.84 ± 8.121 |
| Percent Change at Week 16 | -6.40 ± 8.190 | 0.65 ± 9.404 | -9.75 ± 9.705 | -21.32 ± 8.597 |
Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
| Percentage change in units/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change at Week 8 | 4.12 ± 4.849 | 3.12 ± 5.155 | -3.39 ± 5.395 | -7.69 ± 5.056 |
| Percent Change at Week 16 | 5.28 ± 5.278 | 7.26 ± 5.854 | 6.62 ± 6.011 | -4.45 ± 5.454 |
Baseline bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
| Percentage change in units/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change at Week 8 | -10.55 ± 14.489 | 0.15 ± 16.410 | -27.48 ± 16.847 | -34.96 ± 15.410 |
| Percent Change at Week 16 | -15.86 ± 15.618 | 0.72 ± 17.670 | -8.40 ± 18.100 | -31.43 ± 16.481 |
Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM. units/kg/day=units per kilograms per day.
| Percent change in units/kg/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change at Week 8 | -9.02 ± 7.523 | -2.30 ± 8.674 | -20.39 ± 8.947 | -20.04 ± 8.022 |
| Percent Change at Week 16 | -7.88 ± 7.879 | 0.23 ± 9.119 | -4.04 ± 9.354 | -17.40 ± 8.343 |
Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
| Percent change in units/kg/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change at Week 8 | 6.59 ± 4.929 | 9.05 ± 5.287 | 5.45 ± 5.639 | -1.27 ± 5.152 |
| Percent Change at Week 16 | 6.80 ± 5.328 | 13.00 ± 5.957 | 16.81 ± 6.196 | 4.49 ± 5.520 |
Baseline of bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.
| Percent change in units/kg/day | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 8 | -12.10 ± 14.705 | -0.73 ± 16.650 | -24.83 ± 17.098 | -33.52 ± 15.704 |
| Change at Week 16 | -17.86 ± 15.772 | -0.51 ± 17.860 | -3.73 ± 18.294 | -27.89 ± 16.713 |
All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\< 8.5% or ≥ 8.5%) + Methods of insulin administration (pump or multiple daily injection \[MDI\]) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
| milligrams per deciliter (mg/dL) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 8 | -7.8 ± 6.47 | -9.7 ± 6.77 | -13.2 ± 6.45 | 2.5 ± 6.32 |
| Change at Week 16 | -0.3 ± 6.43 | -8.6 ± 6.76 | -7.2 ± 6.74 | -5.5 ± 6.33 |
All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
| mg/dL | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 8 | -7.9 ± 6.38 | -9.5 ± 6.68 | -12.1 ± 6.34 | 2.4 ± 6.24 |
| Change at Week 16 | 0.1 ± 6.33 | -8.8 ± 6.65 | -6.0 ± 6.63 | -5.1 ± 6.23 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
| Percentage of time | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 8 | 4.4 ± 4.22 | 7.5 ± 4.41 | 8.3 ± 4.20 | -0.3 ± 4.14 |
| Change at Week 16 | -0.3 ± 3.95 | 5.6 ± 4.15 | 3.7 ± 4.13 | 3.0 ± 3.90 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-140 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
| Percentage of time | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 8 | 3.2 ± 3.74 | 5.1 ± 3.89 | 6.5 ± 3.69 | -2.3 ± 3.67 |
| Change at Week 16 | -0.2 ± 3.53 | 4.6 ± 3.69 | 4.0 ± 3.70 | 1.6 ± 3.48 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay below the target range of \<54-70 mg/dL and very below the target range of \<54 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
| Percentage of time | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| TBTR: Change at Week 8 | 0.3 ± 0.47 | 0.0 ± 0.50 | 0.1 ± 0.47 | -0.4 ± 0.46 |
| TBTR: Change at Week 16 | 0.2 ± 0.46 | -0.1 ± 0.50 | 0.1 ± 0.50 | 0.1 ± 0.46 |
| TVBTR: Change at Week 8 | 0.2 ± 0.18 | 0.0 ± 0.20 | -0.1 ± 0.18 | -0.1 ± 0.18 |
| TVBTR: Change at Week 16 | 0.0 ± 0.31 | 0.3 ± 0.33 | 0.3 ± 0.35 | 0.5 ± 0.31 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay TATR \>180-250 mg/dL and TVATR \>250 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.
| precent time | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| TATR: Change at Week 8 | 0.4 ± 2.60 | -2.6 ± 2.75 | -1.9 ± 2.59 | 2.6 ± 2.57 |
| TATR: Change at Week 16 | 2.0 ± 2.38 | -0.9 ± 2.53 | -1.3 ± 2.55 | 0.3 ± 2.37 |
| TVATR: Change at Week 8 | -4.0 ± 2.20 | -3.8 ± 2.32 | -5.1 ± 2.19 | -0.1 ± 2.15 |
| TVATR: Change at Week 16 | -0.4 ± 2.27 | -3.7 ± 2.41 | -1.5 ± 2.40 | -2.3 ± 2.24 |
All participants used a CGM device for glucose monitoring throughout the treatment. Data is reported for event rate (number of events per person-year). Number of events with sensor glucose \<70 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≥70 mg/dL for ≥15 minutes) was assessed. Percentages have been rounded off.
| events per person-year | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Week 8 | 1.74 | 0.90 | 1.75 | 0.94 |
| Week 16 | 0.38 | 2.03 | 1.61 | 2.29 |
All participants used a CGM device for glucose monitoring throughout the treatment. Data are reported for event rates. Event=sensor glucose \>250 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≤180 mg/dL for ≥15 minutes). Percentages have been rounded off.
| events per person-year | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Week 8 | 19.84 | 15.73 | 19.30 | 24.70 |
| Week 16 | 27.23 | 17.47 | 23.72 | 19.85 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Week 8 | 6 | 9 | 9 | 5 |
| Week 16 | 5 | 4 | 3 | 6 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Week 8 | 2 | 7 | 4 | 3 |
| Week 16 | 3 | 3 | 2 | 4 |
All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Week 8 | 4 | 6 | 5 | 5 |
| Week 16 | 2 | 5 | 4 | 2 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 9 | 7 | 7 | 7 |
| Week 8 | 7 | 3 | 3 | 8 |
| Week 16 | 6 | 3 | 4 | 6 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 10 | 6 | 11 | 7 |
| Week 8 | 4 | 6 | 5 | 9 |
| Week 16 | 8 | 5 | 2 | 4 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 1 | 1 | 0 | 0 |
| Week 8 | 0 | 0 | 2 | 0 |
| Week 16 | 0 | 0 | 0 | 0 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 1 | 1 | 1 | 0 |
| Week 8 | 1 | 0 | 2 | 1 |
| Week 16 | 0 | 0 | 0 | 1 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 23 | 22 | 20 | 21 |
| Week 8 | 16 | 16 | 15 | 19 |
| Week 16 | 13 | 13 | 11 | 14 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 22 | 23 | 20 | 20 |
| Week 8 | 15 | 16 | 17 | 19 |
| Week 16 | 16 | 13 | 11 | 15 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 3 | 5 | 4 | 2 |
| Week 8 | 4 | 6 | 5 | 3 |
| Week 16 | 2 | 5 | 4 | 2 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline | 6 | 7 | 5 | 2 |
| Week 8 | 6 | 6 | 6 | 4 |
| Week 16 | 3 | 4 | 3 | 3 |
All participants used a CGM device for glucose monitoring throughout the treatment.
| Percent change | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 8 | -1.2 ± 31.95 | 1.1 ± 45.93 | -10.5 ± 31.79 | 8.0 ± 38.70 |
| Change at Week 16 | 13.5 ± 40.75 | 1.9 ± 32.71 | 14.5 ± 26.19 | 6.6 ± 35.14 |
| Percent change in body weight | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Percent Change at Week 4 | -0.13 ± 0.451 | -2.31 ± 0.473 | -2.71 ± 0.461 | -2.47 ± 0.460 |
| Percent Change at Week 8 | -0.41 ± 0.602 | -3.46 ± 0.629 | -4.81 ± 0.607 | -4.19 ± 0.621 |
| Percent Change at Week 12 | 0.02 ± 0.716 | -3.12 ± 0.738 | -6.14 ± 0.718 | -5.29 ± 0.734 |
| Percent Change at Week 16 | 0.29 ± 0.839 | -3.26 ± 0.865 | -6.43 ± 0.838 | -6.67 ± 0.861 |
| kilograms (kg) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Change at Week 4 | -0.07 ± 0.462 | -2.34 ± 0.484 | -2.59 ± 0.472 | -2.46 ± 0.471 |
| Change at Week 8 | -0.36 ± 0.580 | -3.31 ± 0.608 | -4.51 ± 0.586 | -4.16 ± 0.598 |
| Change at Week 12 | 0.00 ± 0.674 | -2.92 ± 0.696 | -5.73 ± 0.676 | -5.27 ± 0.690 |
| Change at Week 16 | 0.39 ± 0.789 | -2.96 ± 0.814 | -5.95 ± 0.789 | -6.57 ± 0.808 |
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| ≥5% Weight Loss | 2 | 6 | 15 | 15 |
| ≥10% Weight Loss | 0 | 2 | 1 | 3 |
| ≥15% Weight Loss | 0 | 0 | 1 | 0 |
| ≥20% Weight Loss | 0 | 0 | 0 | 0 |
Level 1 hypoglycemia: glucose between \<70-54 mg/dL; Level 2 hypoglycemia: glucose level between \<54 mg/dL; Level 3 hypoglycemia: These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma.
| percentage of participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Level 1 Hypoglycemia | 20.7 | 13.3 | 5.9 | 5.6 |
| Level 2 Hypoglycemia | 31.0 | 50.0 | 47.1 | 66.7 |
| Level 3 Hypoglycemia | 0 | 0 | 0 | 0 |
The baseline period event rate was calculated as (the total number of events) / (14/365.25 \* number of patients). Baseline hypoglycemia events occurred within 14 days prior to first treatment start time (Day 1). The treatment period event rate was calculated as (the total number of events) / (sum of the person-time exposed to the study drug after randomization (in years)). Sum of the person-time exposed to the study drug after randomization is calculated as the time from first to last dose of study drug for all participants in the respective treatment arm.
| events per person-year | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Baseline Period | 7.20 | 9.57 | 7.67 | 15.94 |
| Treatment Period | 2.34 | 6.29 | 7.84 | 6.36 |
DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 milliequivalents per liter \[mEq/L\]), and accompanied by symptoms/signs per the anti-drug antibody (ADA) consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Number of Participants With Diabetic Ketoacidosis (DKA) Events | 0 | 0 | 0 | 0 |
DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 mEq/L), and accompanied by symptoms/signs per the ADA consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| Participants With DKA Events That Led to Hospitalization or Emergency Room Visits During the Study | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An ADE was defined as an AE related to the medical device; in this study, the medical device is the pen device with which the study drug is administered. This included any event that was the result of incomplete user manual information or of incorrect use of the medical device.
| Participants | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| AEs | 23 | 26 | 32 | 17 |
| ADEs | 0 | 0 | 0 | 0 |
| micrograms per milliliter (µg/mL) | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|
| Week 2 | 62.7 ± 43.7 | 43.2 ± 26.7 | 71.6 ± 26.6 |
| Week 4 | 74.1 ± 44.7 | 84.8 ± 42.0 | 124 ± 85.6 |
| Week 6 | 60.5 ± 48.9 | 111 ± 67.2 | 131 ± 88.0 |
| Week 8 | 53.0 ± 44.0 | 175 ± 96.4 | 224 ± 111 |
| Week 12 | 69.2 ± 57.3 | 189 ± 116 | 440 ± 210 |
| Week 16 | 73.0 ± 71.5 | 197 ± 116 | 381 ± 240 |
Collected over From first dose of study drug until 30 days after the last dose of study drug (up to 20 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: All Placebo | 0/29 (0%) | 0/29 (0%) | 21/29 (72.4%) |
| Arm 2: CT-868 Titrated to 1.8 mg | 0/30 (0%) | 0/30 (0%) | 24/30 (80%) |
| Arm 3: CT-868 Titrated to 4.1 mg | 0/34 (0%) | 1/34 (2.9%) | 31/34 (91.2%) |
| Arm 4: CT-868 Titrated to 6.6 mg | 0/18 (0%) | 2/18 (11.1%) | 17/18 (94.4%) |
| Event | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/29 | 0/30 | 0/34 | 1/18 |
| HyponatraemiaMetabolism and nutrition disorders | 0/29 | 0/30 | 0/34 | 1/18 |
| Infected biteInfections and infestations | 0/29 | 0/30 | 1/34 | 0/18 |
| Event | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/29 | 13/30 | 17/34 | 9/18 |
| VomitingGastrointestinal disorders | 0/29 | 4/30 | 8/34 | 8/18 |
| ConstipationGastrointestinal disorders | 3/29 | 6/30 | 12/34 | 5/18 |
| DiarrhoeaGastrointestinal disorders | 2/29 | 6/30 | 6/34 | 6/18 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 4/29 | 4/30 | 4/34 | 6/18 |
| Decreased appetiteMetabolism and nutrition disorders | 4/29 | 6/30 | 6/34 | 6/18 |
| DyspepsiaGastrointestinal disorders | 1/29 | 4/30 | 7/34 | 5/18 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/29 | 5/30 | 5/34 | 5/18 |
| Injection site erythemaGeneral disorders | 0/29 | 2/30 | 3/34 | 4/18 |
| Injection site pruritusGeneral disorders | 0/29 | 1/30 | 3/34 | 4/18 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg | Total |
|---|---|---|---|---|---|
| Mean | 38.0 ± 12.51 | 43.1 ± 13.73 | 41.3 ± 11.77 | 42.2 ± 14.83 | 41.1 ± 13.20 |
| Sex: Female, Male(Participants) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg | Total |
|---|---|---|---|---|---|
| Female | 18 | 19 | 16 | 17 | 70 |
| Male | 11 | 8 | 12 | 10 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 7 | 4 | 19 |
| Not Hispanic or Latino | 26 | 21 | 21 | 23 | 91 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 1 | 5 |
| White | 27 | 26 | 25 | 25 | 103 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| HbA1c Level at Baseline (Stratification Factor)(Participants) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg | Total |
|---|---|---|---|---|---|
| HbA1c <8.5% | 25 | 24 | 23 | 23 | 95 |
| HbA1c ≥8.5% | 4 | 3 | 5 | 4 | 16 |
| Method of Insulin Administration(Participants) | Arm 1: All Placebo | Arm 2: CT-868 Titrated to 1.8 mg | Arm 3: CT-868 Titrated to 4.1 mg | Arm 4: CT-868 Titrated to 6.6 mg | Total |
|---|---|---|---|---|---|
| Automated Insulin Delivery (AID) | 8 | 9 | 8 | 10 | 35 |
| Non-AID (Pump) | 12 | 9 | 9 | 7 | 37 |
| Multiple Daily Injections (MDI) | 9 | 9 | 11 | 10 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Jul 2025, 19 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's 19 months is above that.
Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.
Start moved once since we started tracking on Sep 25, 2026: Oct 2023 → Nov 2023, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CT-868